Exclusive Patent License Agreement Sample Contracts

Aptorum Group Ltd – First Amendment to Exclusive Patent License Agreement (September 5th, 2018)

THIS FIRST AMENDMENT TO EXCLUSIVE PATENT LICENSE AGREEMENT (the "Amendment") is made effective as of 7th June, 2018 by and between Versitech Limited, a company incorporated and existing under the laws of Hong Kong with its office at Room 405A, Cyberport 4, 100 Cyberport Road, Hong Kong (the "Licensor"); and Acticule Life Sciences Limited, with incorporation number CB-324541, a company incorporated and existing under the laws of the Cayman Islands, with its registered office at Floor 4, Willow House, Cricket Square, Grand Cayman KY1-9010, Cayman Islands with its management office at Floor 17, Guangdong Investment Tower, 148 Connaught Road, Central, Hong Kong (the "Company").

Aptorum Group Ltd – VERSITECH LIMITED and ACTICULE LIFE SCIENCES LIMITED EXCLUSIVE PATENT LICENSE AGREEMENT (September 5th, 2018)
Aptorum Group Ltd – VERSITECH LIMITED and ACTICULE LIFE SCIENCES LIMITED EXCLUSIVE PATENT LICENSE AGREEMENT (September 5th, 2018)
Aptorum Group Ltd – First Amendment to Exclusive Patent License Agreement (September 5th, 2018)

THIS FIRST AMENDMENT TO EXCLUSIVE PATENT LICENSE AGREEMENT (the "Amendment") is made effective as of 7th June, 2018 by and between Versitech Limited, a company incorporated and existing under the laws of Hong Kong with its office at Room 405A, Cyberport 4, 100 Cyberport Road, Hong Kong (the "Licensor"); and Acticule Life Sciences Limited, with incorporation number CB-324541, a company incorporated and existing under the laws of the Cayman Islands, with its registered office at Floor 4, Willow House, Cricket Square, Grand Cayman KY1-9010, Cayman Islands with its management office at Floor 17, Guangdong Investment Tower, 148 Connaught Road, Central, Hong Kong (the "Company").

Tiziana Life Sciences plc – EXCLUSIVE PATENT LICENSE AGREEMENT BWH Agreement No: A225080 BWH Case No: BWH 24334 (August 23rd, 2018)

This Exclusive Patent License Agreement ("Agreement") is made as of the last signature date of this Agreement, ("Effective Date"), by and between Tiziana Pharma Ltd., a company incorporated in England and Wales, having a principal place of business at 3rd Floor, 11-12 St. James Square, London, United Kingdom SW1Y 4LB ("Company") and The Brigham and Women's Hospital, Inc., a not-for-profit Massachusetts corporation, with a principal place of business at 75 Francis Street, Boston, Massachusetts 02115 ("Hospital"), each referred to herein individually as a "Party" and collectively as the "Parties".

Aridis Pharmaceuticals, Inc. – The BRIGHAM AND WOMENS HOSPITAL, INC. EXCLUSIVE PATENT LICENSE AGREEMENT BWH Agreement No: 107605.05 BWH Case Nos: 10706, 11049 (July 18th, 2018)

This License Agreement (Agreement) is made as of the tenth day of November, 2010 (Effective Date), by and between Aridis Pharmaceuticals, LLC, a California corporation, having an office at 5941 Optical Court, San Jose, CA 95138 (Company) and The Brigham and Womens Hospital, Inc., a not-for-profit Massachusetts corporation, with a principal place of business at 75 Francis Street, Boston, Massachusetts 02115 (Hospital), each referred to herein individually as a Party and collectively as the Parties.

Aridis Pharmaceuticals, Inc. – The BRIGHAM AND WOMENS HOSPITAL, INC. FIRST AMENDMENT to EXCLUSIVE PATENT LICENSE AGREEMENT BWH Agreement No: 107605.06 BWH Case Nos: 10706, 11049 (July 18th, 2018)

This First Amendment to the License Agreement (as defined below) (First Amendment) is made as of the eighteenth day of February, 2016 (First Amendment Effective Date), by and between Aridis Pharmaceuticals, Inc, a Delaware corporation, having an office at 5941 Optical Court, San Jose, CA 95138 (Company) and The Brigham and Womens Hospital, Inc., a not-for-profit Massachusetts corporation, with a principal place of business at 75 Francis Street, Boston, Massachusetts 02115 (Hospital), each referred to herein individually as a Party and collectively as the Parties.

BioNano Genomics, Inc – Non-Exclusive Patent License Agreement (June 28th, 2018)

This non-exclusive patent license agreement (Agreement), by and between Q Biotechnology C.V. (Licensor), a Dutch company with a place of business at Spoorstraat 50, 5911 KJ Venlo, the Netherlands and BioNano Genomics, Inc (Licensee), a Delaware (USA) corporation with a place of business at 9640 Town Centre Drive, Suite 100, San Diego, CA 92121, USA is made effective as of May 1st, 2014 (Effective Date).

BioNano Genomics, Inc – AMENDMENT to the NON-EXCLUSIVE PATENT LICENSE AGREEMENT Dated 01 May 2014 (The Amendment) (June 28th, 2018)
Rubius Therapeutics, Inc. – WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH and RUBIUS THERAPEUTICS, INC. EXCLUSIVE PATENT LICENSE AGREEMENT (June 22nd, 2018)

This Agreement, effective as of January 28, 2016, (the EFFECTIVE DATE), is by and between the Whitehead Institute for Biomedical Research (WHITEHEAD), a Delaware corporation, with a principal office at Nine Cambridge Center, Cambridge, MA 02142, and Rubius Therapeutics, Inc. (COMPANY), formerly known as VL26, Inc., a Delaware corporation, with a principal place of business at 620 Memorial Drive, Suite 100 West, Cambridge, MA 02139.

Translate Bio, Inc. – Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. Double Asterisks Denote Omissions. MASSACHUSETTS INSTITUTE OF TECHNOLOGY AND SHIRE AG EXCLUSIVE PATENT LICENSE AGREEMENT (M.I.T. Case No. [**]) (June 1st, 2018)

This Agreement, effective as of the date set forth above the signatures of the parties below (the EFFECTIVE DATE), is between the Massachusetts Institute of Technology (MIT), a Massachusetts corporation, with a principal office at 77 Massachusetts Avenue, Cambridge, MA 02139-4307 and Shire AG (COMPANY), a company organized under the laws of Switzerland having a place of business at Route de Crassier 15, Business Park Terre Bonne, Chemin de Terre Bonne, Eysins 1262, Vaud, Switzerland.

Rubius Therapeutics, Inc. – WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH and RUBIUS THERAPEUTICS, INC. EXCLUSIVE PATENT LICENSE AGREEMENT (May 24th, 2018)

This Agreement, effective as of January 28, 2016, (the EFFECTIVE DATE), is by and between the Whitehead Institute for Biomedical Research (WHITEHEAD), a Delaware corporation, with a principal office at Nine Cambridge Center, Cambridge, MA 02142, and Rubius Therapeutics, Inc. (COMPANY), formerly known as VL26, Inc., a Delaware corporation, with a principal place of business at 620 Memorial Drive, Suite 100 West, Cambridge, MA 02139.

BioNano Genomics, Inc – Non-Exclusive Patent License Agreement (May 14th, 2018)

This non-exclusive patent license agreement (Agreement), by and between Q Biotechnology C.V. (Licensor), a Dutch company with a place of business at Spoorstraat 50, 5911 KJ Venlo, the Netherlands and BioNano Genomics, Inc (Licensee), a Delaware (USA) corporation with a place of business at 9640 Town Centre Drive, Suite 100, San Diego, CA 92121, USA is made effective as of May 1st, 2014 (Effective Date).

BioNano Genomics, Inc – AMENDMENT to the NON-EXCLUSIVE PATENT LICENSE AGREEMENT Dated 01 May 2014 (The Amendment) (May 14th, 2018)
Aridis Pharmaceuticals, Inc. – The BRIGHAM AND WOMENS HOSPITAL, INC. EXCLUSIVE PATENT LICENSE AGREEMENT BWH Agreement No: 107605.05 BWH Case Nos: 10706, 11049 (April 20th, 2018)

This License Agreement (Agreement) is made as of the tenth day of November, 2010 (Effective Date), by and between Aridis Pharmaceuticals, LLC, a California corporation, having an office at 5941 Optical Court, San Jose, CA 95138 (Company) and The Brigham and Womens Hospital, Inc., a not-for-profit Massachusetts corporation, with a principal place of business at 75 Francis Street, Boston, Massachusetts 02115 (Hospital), each referred to herein individually as a Party and collectively as the Parties.

Aridis Pharmaceuticals, Inc. – The BRIGHAM AND WOMENS HOSPITAL, INC. FIRST AMENDMENT to EXCLUSIVE PATENT LICENSE AGREEMENT BWH Agreement No: 107605.06 BWH Case Nos: 10706, 11049 (April 20th, 2018)

This First Amendment to the License Agreement (as defined below) (First Amendment) is made as of the eighteenth day of February, 2016 (First Amendment Effective Date), by and between Aridis Pharmaceuticals, Inc, a Delaware corporation, having an office at 5941 Optical Court, San Jose, CA 95138 (Company) and The Brigham and Womens Hospital, Inc., a not-for-profit Massachusetts corporation, with a principal place of business at 75 Francis Street, Boston, Massachusetts 02115 (Hospital), each referred to herein individually as a Party and collectively as the Parties.

Creative Beauty Supply of New Jersey CORP – Massachusetts Institute of Technology Nonexclusive Patent License Agreement (April 17th, 2018)

This Agreement, effective as of February 1, 2018 (the "EFFECTIVE DATE"), is between the Massachusetts Institute of Technology ("MIT"), a Massachusetts non-profit corporation, with a principal office at 77 Massachusetts Avenue, Cambridge, MA 02139-4307 and IIOT-OXYS, Inc. ("COMPANY"), a corporation, with a principal place of business at 705 Cambridge St. Cambridge, MA 02141.

Rubius Therapeutics, Inc. – WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH and RUBIUS THERAPEUTICS, INC. EXCLUSIVE PATENT LICENSE AGREEMENT (April 13th, 2018)

This Agreement, effective as of January 28, 2016, (the EFFECTIVE DATE), is by and between the Whitehead Institute for Biomedical Research (WHITEHEAD), a Delaware corporation, with a principal office at Nine Cambridge Center, Cambridge, MA 02142, and Rubius Therapeutics, Inc. (COMPANY), formerly known as VL26, Inc., a Delaware corporation, with a principal place of business at 620 Memorial Drive, Suite 100 West, Cambridge, MA 02139.

Cellectis S.A. – Third Amendment to Exclusive Patent License Agreement (Epla) (March 13th, 2018)

THIS THIRD AMENDMENT TO EXCLUSIVE PATENT LICENSE AGREEMENT (the Third Amendment) is made and entered effective as of the date of the last signature (the Third Amendment Effective Date), by and between Regents of the University of Minnesota (the University), a Minnesota constitutional corporation under the laws of the state of Minnesota, and Cellectis SA, a Corporation under the laws of the France having a place of business at 8, rue de la Croix Jarry, 75013 Paris, France (the Licensee) each a Party and collectively, the Parties).

Translate Bio, Inc. – Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. Double Asterisks Denote Omissions. MASSACHUSETTS INSTITUTE OF TECHNOLOGY AND SHIRE AG EXCLUSIVE PATENT LICENSE AGREEMENT (M.I.T. Case No. [**]) (February 9th, 2018)

This Agreement, effective as of the date set forth above the signatures of the parties below (the EFFECTIVE DATE), is between the Massachusetts Institute of Technology (MIT), a Massachusetts corporation, with a principal office at 77 Massachusetts Avenue, Cambridge, MA 02139-4307 and Shire AG (COMPANY), a company organized under the laws of Switzerland having a place of business at Route de Crassier 15, Business Park Terre Bonne, Chemin de Terre Bonne, Eysins 1262, Vaud, Switzerland.

ARMO BioSciences, Inc. – Confidential Treatment Requested Exclusive Patent License Agreement (December 29th, 2017)

THIS EXCLUSIVE PATENT LICENSE AGREEMENT (this Agreement), dated as of December 12, 2012 (the Effective Date), is by and between Merck, Sharp & Dohme Corporation, a corporation organized and existing under the laws of New Jersey (hereinafter referred to as Merck), and Targenics, Inc., a corporation organized and existing under the laws of Delaware (hereinafter referred to as Licensee). Merck and Licensee are sometimes referred to herein individually as a Party and collectively as the Parties.

Solid Biosciences, LLC – Exclusive Patent License Agreement (December 29th, 2017)

This exclusive patent license agreement (Agreement) is dated and effective as of the date of last signature (the Effective Date), and is made between the University of Washington, a public institution of higher education and an agency of the state of Washington, acting through UW CoMotion (University), and Solid GT, LLC, a limited liability company under the laws of the state of Delaware (Company), (individually Party or collectively Parties).

ARMO BioSciences, Inc. – CONFIDENTIAL TREATMENT REQUESTED Amendment No. 2 to the Exclusive Patent License Agreement Between Merck Sharp & Dohme Corp. And ARMO Biosciences Inc. (December 29th, 2017)

This Amendment No. 2 (Amendment) is entered into as of July 11, 2017 between ARMO BIOSCIENCES INC. (formerly Targenics, Inc.), a corporation organized under the laws Delaware (Licensee) and MERCK SHARP & DOHME CORP., a corporation organized under the laws of New Jersey (MERCK) to amend the terms of the Exclusive Patent License Agreement between the Parties, effective December 10, 2012, as amended on the same date (the Agreement)

ARMO BioSciences, Inc. – Amendment No. 1 to the Exclusive Patent License Agreement (December 29th, 2017)

THIS Amendment No. 1 to the Exclusive Patent License Agreement (Amendment No. 1), dated as of December 12, 2012 (the Effective Date), is by and between Merck, Sharpe and Dohme Corporation, a corporation organized and existing under the laws of New Jersey (hereinafter referred to as Merck), and Targenics, Inc., a corporation organized and existing under the laws of Delaware (hereinafter referred to as Licensee). Merck and Licensee are sometimes referred to herein individually as a Party and collectively as the Parties.

ARMO BioSciences, Inc. – CONFIDENTIAL TREATMENT REQUESTED Amendment No. 2 to the Exclusive Patent License Agreement Between Merck Sharp & Dohme Corp. And ARMO Biosciences Inc. (November 22nd, 2017)

This Amendment No. 2 (Amendment) is entered into as of July 11, 2017 between ARMO BIOSCIENCES INC. (formerly Targenics, Inc.), a corporation organized under the laws Delaware (Licensee) and MERCK SHARP & DOHME CORP., a corporation organized under the laws of New Jersey (MERCK) to amend the terms of the Exclusive Patent License Agreement between the Parties, effective December 10, 2012, as amended on the same date (the Agreement)

ARMO BioSciences, Inc. – Amendment No. 1 to the Exclusive Patent License Agreement (November 22nd, 2017)

THIS Amendment No. 1 to the Exclusive Patent License Agreement (Amendment No. 1), dated as of December 12, 2012 (the Effective Date), is by and between Merck, Sharpe and Dohme Corporation, a corporation organized and existing under the laws of New Jersey (hereinafter referred to as Merck), and Targenics, Inc., a corporation organized and existing under the laws of Delaware (hereinafter referred to as Licensee). Merck and Licensee are sometimes referred to herein individually as a Party and collectively as the Parties.

ARMO BioSciences, Inc. – Confidential Treatment Requested Exclusive Patent License Agreement (November 22nd, 2017)

THIS EXCLUSIVE PATENT LICENSE AGREEMENT (this Agreement), dated as of December 12, 2012 (the Effective Date), is by and between Merck, Sharp & Dohme Corporation, a corporation organized and existing under the laws of New Jersey (hereinafter referred to as Merck), and Targenics, Inc., a corporation organized and existing under the laws of Delaware (hereinafter referred to as Licensee). Merck and Licensee are sometimes referred to herein individually as a Party and collectively as the Parties.

Oxis International – University of Minnesota EXCLUSIVE PATENT LICENSE AGREEMENT (August 11th, 2017)

THIS EXCLUSIVE PATENT LICENSE AGREEMENT (this "Agreement") is made by and between Regents of the University of Minnesota, a constitutional corporation under the laws of the state of Minnesota, having a place of business at 200 Oak Street, SE, Suite 280, Minneapolis, Minnesota 55455 (the "University"), and the Licensee identified below. The University and the Licensee agree that:

Knight Knox Development Corp. – Exclusive Patent License Agreement Between Analog Biosciences, Inc. And Artelo Biosciences, Inc. Exclusive Patent License Agreement (August 4th, 2017)

This exclusive license agreement ("Agreement") is effective July 3, 2017 ("Effective Date"), by and between (a) Analog Biosciences, Inc. ("Licensor"), a Nevada corporation, having an office at 1340 Specialty Dr., Ste i, Vista, CA 92081, and (b) Artelo Biosciences, Inc. ("Licensee"), a Nevada corporation having a principal place of business at 564 Wedge Lane, Fernley, NV 89408. Licensor and Licensee may be referred to herein, on occasion, individually as "Party" or collectively as "Parties".

Knight Knox Development Corp. – Exclusive Patent License Agreement Between Analog Sciences, Inc. And Artelo Biosciences, Inc. (August 4th, 2017)

This exclusive license agreement ("Agreement") is effective March 24, 2017 ("Effective Date"), by and between (a) Analog Biosciences, Inc. ("Licensor"), a Nevada corporation, having an office at 1340 Specialty Dr., Ste i, Vista, CA 92081, and (b) Artelo Biosciences, Inc. ("Licensee"), a Nevada corporation having a principal place of business at 564 Wedge Lane, Fernley, NV 89408. Licensor and Licensee may be referred to herein, on occasion, individually as "Party" or collectively as "Parties".

Solid Biosciences, LLC – Exclusive Patent License Agreement (August 4th, 2017)

This exclusive patent license agreement (Agreement) is dated and effective as of the date of last signature (the Effective Date), and is made between the University of Washington, a public institution of higher education and an agency of the state of Washington, acting through UW CoMotion (University), and Solid GT, LLC, a limited liability company under the laws of the state of Delaware (Company), (individually Party or collectively Parties).

Calyxt, Inc. – University of Minnesota Exclusive Patent License Agreement (July 3rd, 2017)

THIS EXCLUSIVE PATENT LICENSE AGREEMENT (this Agreement) is made by and between Regents of the University of Minnesota, a constitutional corporation under the laws of the state of Minnesota, having a place of business at 200 Oak Street, SE, Suite 280, Minneapolis, Minnesota 55455 (the University), and the Licensee identified below. The University and the Licensee agree that:

Calyxt, Inc. – University of Minnesota Exclusive Patent License Agreement (June 23rd, 2017)

THIS EXCLUSIVE PATENT LICENSE AGREEMENT (this Agreement) is made by and between Regents of the University of Minnesota, a constitutional corporation under the laws of the state of Minnesota, having a place of business at [*****] (the University), and the Licensee identified below. The University and the Licensee agree that:

Calyxt, Inc. – University of Minnesota Exclusive Patent License Agreement (June 16th, 2017)

THIS EXCLUSIVE PATENT LICENSE AGREEMENT (this Agreement) is made by and between Regents of the University of Minnesota, a constitutional corporation under the laws of the state of Minnesota, having a place of business at [*****] (the University), and the Licensee identified below. The University and the Licensee agree that:

Therapeutic Solutions International, Inc. – Exclusive Patent License Agreement (June 12th, 2017)

This Exclusive Patent License Agreement (the Agreement and/or EPLA) is made and entered into by and between Therapeutic Solutions International, Inc., a corporation organized under Nevada law (hereinafter the Licensor), having its principle office at 4093 Oceanside Blvd., Suite B, Oceanside CA, 92056, and Emvolio, Inc., a corporation organized under the laws of Delaware (hereinafter the Licensee), its principle office being located in Oceanside, California. Licensor and Licensee are sometimes referred to herein individually as a Party and collectively as the Parties. The Parties agree as follows: